The clinical role of CT/PET in oncology: an update

Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology

Cancer is a fatal disease and the second most cause of death worldwide. Treatment of cancer is a complex process and requires a multi-modality-based approach. Cancer detection and treatment starts with screening/diagnosis and continues till the patient is alive. Screening/diagnosis of the disease is the beginning of cancer management and continued with the staging of the disease, planning and delivery of treatment, treatment monitoring, and ongoing monitoring and follow-up. Imaging plays an important role in all stages of cancer management. Conventional oncology practice considers that all patients are similar in a disease type, whereas biomarkers subgroup the patients in a disease type which leads to the development of precision oncology. The utilization of the radiomic process has facilitated the advancement of diverse imaging biomarkers that find application in precision oncology. The role of imaging biomarkers and artificial intelligence (AI) in oncology has been investigated by many researchers in the past. The existing literature is suggestive of the increasing role of imaging biomarkers and AI in oncology. However, the stability of radiomic features has also been questioned. The radiomic community has recognized that the instability of radiomic features poses a danger to the global generalization of radiomic-based prediction models. In order to establish radiomic-based imaging biomarkers in oncology, the robustness of radiomic features needs to be established on a priority basis. This is because radiomic models developed in one institution frequently perform poorly in other institutions, most likely due to radiomic feature instability. To generalize radiomic-based prediction models in oncology, a number of initiatives, including Quantitative Imaging Network (QIN), Quantitative Imaging Biomarkers Alliance (QIBA), and Image Biomarker Standardisation Initiative (IBSI), have been launched to stabilize the radiomic features.

Design and Evaluation of MeVisLab Networks for Co-Registration and Cropping of Positron Emission Tomography/Computed Tomography Scans

Objective

The aim of the present study was to design and evaluate two MeVisLab networks, one for co-registration of positron emission tomography/computed tomography (PET/CT) images and second for cropping the co-registered PET/CT images.

Materials and Methods

Two MeVisLab networks, one to co-register and export PET/CT DICOM images and second for cropping the co-registered PET/CT images were designed using different modules of registration toolkit MERIT. One hundred and twenty-five PET/CT studies were exported from Siemens and GE scanners in DICOM format. These images were co-registered and cropped with our designed networks. The images co-registered with our network were compared visually with the co-registered images of same PET/CT studies on vendor provided workstations by an experienced nuclear medicine physician (NMP). The perfection of the cropping of co-registered images was also assessed visually.

Results

Visually, NMP found all 125 images co-registered using the network designed in our study similar to the co-registered images of vendor provided workstations. Furthermore, the cropping of all co-registered images was perfectly done by our network.

Conclusion

Two MeVisLab networks designed and evaluated in the present study can be used for co-registration of PET/CT DICOM images and cropping the co-registered PET/CT images.

Expression of glucose transporter-1, hypoxia-inducible factor-1α, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review

This report presents a case of nasopharyngeal diffuse large B-cell lymphoma and a literature review concerning the use of [(18)F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). A 37-year old man was admitted to hospital complaining of nasal secretions with minor epistaxis and a 20-year history of snoring. Nasal endoscopy found diffuse swelling in the nasopharynx and a biopsy was performed. Prior to chemotherapy, FDG-PET/CT showed soft tissue diffuse thickening and FDG accumulation in the nasopharynx and bilateral cervical lymph nodes; FDG did not accumulate elsewhere. After four cycles of chemotherapy (rituximab, cyclo phosphamide, doxorubicin, vincristine) and prednisone treatment, FDG-PET/CT showed that FDG still accumulated in the nasopharynx and bilateral cervical lymph nodes, therefore radiotherapy was initiated. At 1 year, FDG-PET/CT showed no FDG accumulation. Immunohistochemical analysis revealed that the tumour was positive for phosphorylated protein kinase B (Akt), suggesting that FDG uptake may be associated with factors activated by the phosphatidylinositol 3-kinase/Akt signalling pathway.

Advances in radiation therapy for lung cancer

OBJECTIVES

To trace the history of radiotherapy and present the latest advances in radiation treatment planning, techniques, and delivery for the treatment of non-small cell lung cancer.

DATA SOURCES

Textbooks, manuals, journals. and internet sites.

CONCLUSION

After the introduction of computed tomography into radiation oncology (RO), technology advanced in the development of newer equipment for designing, planning, and delivering treatment. RO is pushing the limits of higher doses, under the theory that higher doses kill more cancer cells. The outcomes are promising. Nurses can articulate these technological changes and help patients through the highly technical process.

IMPLICATIONS FOR NURSING PRACTICE

Knowledge of new technology and treatment strategies for patients with lung cancer will assist nurses in patient education and outcomes of therapy.

Multimodal imaging approaches: PET/CT and PET/MRI

Multimodality imaging, specifically PET/CT, brought a new perspective into the fields of clinical and preclinical imaging. Clinical cases have shown, that the combination of anatomical structures, revealed from CT, and the functional information from PET into one image, with high fusion accuracy, provides an advanced diagnostic tool and research platform. Although PET/CT is already an established clinical tool it still bears some limitations. A major drawback is that CT provides only limited soft tissue contrast and exposes the patient or animal, being studied, to a significant radiation dose. Since PET and CT scanner are hard-wired back to back and share a common patient bed, PET/CT does not allow simultaneous data acquisition. This temporal mismatch causes image artefacts by patient movement between the two scans or by respiration motion. To overcome these limitations, recent research concentrates on the combination of PET and MRI into one single machine. The goal of this development is to integrate the PET detectors into the MRI scanner which would allow simultaneous data acquisition, resulting in combined functional and morphological images with an excellent soft tissue contrast, very good spatial resolution of the anatomy and very accurate temporal and spatial image fusion. Additionally, since MRI provides also functional information such as blood oxygenation level dependant (BOLD) imaging or spectroscopy, PET/MRI could even provide multi-functional information of physiological processes in vivo. First experiments with PET/MRI prototypes showed very promising results, indicating its great potential for clinical and preclinical imaging.

Role of low-dose, noncontrast computed tomography from integrated positron emission tomography/computed tomography in evaluating incidental 2-deoxy-2-[F-18]fluoro-D-glucose-avid colon lesions

PURPOSE

To assess the contribution of concurrent low-dose, noncontrast CT in the assessment of the malignant potential of incidental focal 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-avid colonic lesions on positron emission tomography/computed tomography (PET/CT).

PROCEDURES

Routine FDG-PET/CT scans were reviewed for identification of focal FDG-avid colon lesions, and the CT component was independently reviewed for an anatomical lesion and malignant potential based on CT criteria. Clinical, endoscopic, and histopathology follow-up was obtained.

RESULTS

A total of 85/2,916 (3%) oncology FDG-PET/CT scans had incidental focal colon lesions. Clinical and/or endoscopic follow-up was available in 83/85 (98%) patients. Focal, corresponding CT lesions were found in 44/83 (53%) patients, but features of malignancy were not assessable. Of the 44 patients with a final diagnosis, 32/44 (73%) were FDG-PET/CT true positives; 5/44 (11%) were false positives; and 7/44 (16%) had inconclusive FDG-PET/CT findings.

CONCLUSIONS

Concurrent low-dose, noncontrast CT improves localization, but does not provide independent information on the malignant potential of incidental focal colonic activity on FDG-PET/CT.

PET/CT imaging: what radiologists need to know

Positron emission tomography (PET)/computed tomography (CT) imaging is frequently requested in Oncology. Radiologists and nuclear medicine physicians are often asked to perform a panel of imaging examinations as part of the initial staging or follow-up of cancer patients. Medical imaging must therefore integrate polyvalent skills enabling imaging specialists to understand and interpret all types of images. In this context, PET imaging combined with non-enhanced CT, and diagnostic quality contrast-enhanced CT scan and optimisation of CT settings, is part of this multidisciplinary approach requiring the specific skills of a radiologist and a nuclear medicine physician. This approach must therefore be conducted in both directions: radiologists and nuclear medicine physicians should both know how to correlate PET and CT images, while preserving the specificities of each discipline. Radiologists need to be aware of several aspects of PET imaging: PET technology, the examination procedure and injection of iodinated contrast agent for high quality diagnostic CT, ideally followed by double interpretation of CT images, PET images and fused images. Radiologists should be familiar with PET imaging, as this procedure may be associated with several pitfalls and artefacts that need interpretation by a trained specialist. The authors analyse the examination technique of PET combined with non-enhanced and/or contrast-enhanced CT and the proposals for optimal interpretation of normal or pathological PET/CT fusion images.